文献速递糖尿病

胰岛素抵抗稳态模型评估与糖尿病合并急性冠脉综合征患者的生存

Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome.
PubMed 文献 · J Clin Endocrinol Metab · 2018-01-01

本研究基于阿格列扎心血管结局试验,在未使用胰岛素的2型糖尿病合并急性冠脉综合征患者中,评估基线HOMA-IR(n=4303)及治疗中HOMA-IR变化(n=3568)与死亡或主要不良心血管事件风险的关系。结果显示,校正NT-proBNP后,HOMA-IR与死亡风险无关,且与主要不良心血管事件无关。

要点

  • 基线HOMA-IR升高与死亡风险降低相关(HR 0.79),但校正NT-proBNP后关联消失(HR 0.99)。
  • 基线HOMA-IR与主要不良心血管事件无关。
  • 治疗中HOMA-IR变化与死亡或主要不良心血管事件无关。

核心结论

  • 校正NT-proBNP水平后,HOMA-IR评估的胰岛素抵抗与2型糖尿病合并急性冠脉综合征患者的死亡或主要不良心血管事件风险无关。

研究设计与样本

  • 研究基于阿格列扎对2型糖尿病合并急性冠脉综合征患者心血管结局的试验,比较过氧化物酶体增殖物激活受体-α/γ激动剂阿格列扎与安慰剂。
  • 在未接受胰岛素治疗的患者中,评估基线HOMA-IR(n=4303)或研究治疗中HOMA-IR变化(n=3568)与死亡或主要不良心血管事件(心血管死亡、心肌梗死和卒中)风险的关系。

主要发现

  • 未校正分析中,基线HOMA-IR每增加一倍与死亡风险降低相关(HR: 0.79, 95% CI: 0.68至0.91, P = 0.002)。
  • 校正24个标准人口学和临床变量对上述关联影响极小。
  • 进一步校正NT-proBNP后,HOMA-IR与死亡的关联不再存在(校正HR: 0.99, 95% CI: 0.83至1.19, P = 0.94)。
  • 基线HOMA-IR与主要不良心血管事件无关,研究治疗中HOMA-IR变化与死亡或主要不良心血管事件无关。

关键数值与推荐

  • 基线HOMA-IR每增加一倍与死亡风险的未校正HR为0.79(95% CI: 0.68至0.91, P = 0.002)。
  • 校正NT-proBNP后,基线HOMA-IR每增加一倍与死亡风险的校正HR为0.99(95% CI: 0.83至1.19, P = 0.94)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Insulin resistance has been linked to development and progression of atherosclerosis and is present in most patients with type 2 diabetes. Whether the degree of insulin resistance predicts adverse outcomes in patients with type 2 diabetes and acute coronary syndrome (ACS) is uncertain. DESIGN: The Effect of Aleglitazar on Cardiovascular Outcomes after Acute Coronary Syndrome in Patients with Type 2 Diabetes Mellitus trial compared the peroxisome proliferator-activated receptor-α/γ agonist aleglitazar with placebo in patients with type 2 diabetes and recent ACS. In participants not treated with insulin, we determined whether baseline homeostasis model assessment of insulin resistance (HOMA-IR; n = 4303) or the change in HOMA-IR on assigned study treatment (n = 3568) was related to the risk of death or major adverse cardiovascular events (cardiovascular death, myocardial infarction, and stroke) in unadjusted and adjusted models. Because an inverse association of HOMA-IR with N-terminal pro-B-type natriuretic peptide (NT-proBNP) has been described, we specifically examined effects of adjustment for the latter. RESULTS: In unadjusted analysis, twofold higher baseline HOMA-IR was associated with lower risk of death [hazard ratio (HR): 0.79, 95% CI: 0.68 to 0.91, P = 0.002]. Adjustment for 24 standard demographic and clinical variables had minimal effect on this association. However, after further adjustment for NT-proBNP, the association of HOMA-IR with death was no longer present (adjusted HR: 0.99, 95% CI: 0.83 to 1.19, P = 0.94). Baseline HOMA-IR was not associated with major adverse cardiovascular events, nor was the change in HOMA-IR on study treatment associated with death or major adverse cardiovascular events. CONCLUSIONS: After accounting for levels of NT-proBNP, insulin resistance assessed by HOMA-IR is not related to the risk of death or major adverse cardiovascular events in patients with type 2 diabetes and ACS.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Stähli BE, Nozza A, Schrieks IC, et al. Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome. J Clin Endocrinol Metab. 2018. PMID: 29659887. doi:10.1210/jc.2017-02772

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。